Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Alnylam Pharmaceuticals history
Alnylam Pharmaceuticals company history timeline
In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion’s belt.
In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms.
On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Isis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus.
Alnylam has now exceeded its goals from the first two such plans, growing its market cap from $416 million at the start of 2011 to over $13 billion today.
In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production.
In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia.
In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million.
In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors.
It employs more than 1,500 employees, the vast majority of which are in Massachusetts, and while the company is not yet profitable, it ended 2020 with product revenue of $306 million.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol.
Top-Ranked company for 2021: Collegium Pharmaceuticals
Rate Alnylam Pharmaceuticals' efforts to communicate its history to employees.
Alnylam Pharmaceuticals jobs
Do you work at Alnylam Pharmaceuticals?
Is Alnylam Pharmaceuticals' vision a big part of strategic planning?
Alnylam Pharmaceuticals competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Merck | 1891 | $64.2B | 74,000 | 1,332 |
| Johnson & Johnson | 1886 | $88.8B | 134,500 | 1,764 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 288 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 690 |
| Regeneron | 1988 | $14.2B | 9,123 | 361 |
| Forest Laboratories | 1954 | $3.6B | 6,200 | - |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Sarepta Therapeutics | 1980 | $1.9B | 840 | 27 |
| Acorda Therapeutics | 1995 | $117.6M | 344 | - |
| Ironwood Pharmaceuticals | 1998 | $351.4M | 219 | 1 |
Alnylam Pharmaceuticals history FAQs
Zippia gives an in-depth look into the details of Alnylam Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alnylam Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Alnylam Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alnylam Pharmaceuticals. The data presented on this page does not represent the view of Alnylam Pharmaceuticals and its employees or that of Zippia.
Alnylam Pharmaceuticals may also be known as or be related to Alnylam Pharmaceuticals, Alnylam Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc. and Alnylam Pharmaceuticals, Inc.